NextBillion - An Initiative of the William Davidson Institute at the University of Michigan

Monday, March 11, 2013

An evaluation of the design of the pilot Advance Market Commitment (AMC) for pneumococcal vaccines published today shines a light on the groundbreaking funding mechanism which has already helped vaccinate 13 million children against the world’s biggest childhood killer.

The AMC process and design evaluation’s major findings highlight four key factors that enabled the GAVI Alliance to turn the AMC concept into a successful and innovative funding mechanism to ensure pneumococcal vaccines reach children quicker than ever before.

“Pneumococcal vaccines are protecting the lives of children in many of the world’s poorest countries right now,” said Dr Seth Berkley, CEO of the GAVI Alliance. “Through the pilot AMC, GAVI has been able to help immunise more than 13 million children in developing countries with a sophisticated conjugate vaccine that in the past would have taken a decade to reach them.”